CareDx, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CareDx, Inc. on July 20, 2021, covering events occurring on July 19, 2021. The filing reports the appointment of a new senior executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
Effective July 19, 2021, Alex Johnson was appointed as Chief Business Officer and Head of Testing Services. Mr. Johnson previously served as Senior Vice President, Products, Cell Therapy & Business Development since May 2020. His appointment includes a new compensation package and equity grants.
Management Commentary and Compensation Details
- Base Salary: Annualized salary set at $375,000.
- Performance Bonus: Eligible for an annual bonus of up to 60% of base salary for fiscal year 2021.
- Equity Grants:
- 13,333 stock options granted on July 19, 2021, vesting 25% on the one-year anniversary and monthly thereafter.
- 13,333 restricted stock units (RSUs) granted on July 19, 2021, vesting 25% on the one-year anniversary and annually thereafter.
- Employment Terms: Employment is on an "at-will" basis. The company also executed standard change of control and indemnification agreements.
Investor Verification Points
- Verify the full text of the Promotion Letter (Exhibit 10.1) for complete terms and conditions.
- Confirm the impact of the new equity grants on total share count and dilution.
- Review Mr. Johnson's prior role at Diadexus, Inc., noting the company filed for bankruptcy in June 2016, to assess potential reputational or operational risks.
- Monitor future filings for adjustments to salary or bonus percentages by the Compensation Committee.